- 全部删除
您的购物车当前为空
TQ05310为口服活性的IDH2突变型抑制剂,特异性针对IDH2-R140Q (IC50=136.9 nM)及IDH2-R172K (IC50=37.9 nM)两种突变体。该化合物通过抑制突变IDH2的酶活性以降低2-羟戊二酸(2-HG)的生成,进而诱导携带IDH2-R140Q和IDH2-R172K突变的细胞分化。此外,TQ05310亦被应用于急性髓系白血病的相关研究。

TQ05310为口服活性的IDH2突变型抑制剂,特异性针对IDH2-R140Q (IC50=136.9 nM)及IDH2-R172K (IC50=37.9 nM)两种突变体。该化合物通过抑制突变IDH2的酶活性以降低2-羟戊二酸(2-HG)的生成,进而诱导携带IDH2-R140Q和IDH2-R172K突变的细胞分化。此外,TQ05310亦被应用于急性髓系白血病的相关研究。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 10 mg | 待询 | 10-14周 | |
| 50 mg | 待询 | 10-14周 |
| 产品描述 | TQ05310 is an orally active inhibitor of mutant IDH2, targeting both IDH2-R140Q (IC50=136.9 nM) and IDH2-R172K (IC50=37.9 nM) mutations. This compound suppresses the production of 2-hydroxyglutarate (2-HG) by inhibiting the enzymatic activity of mutant IDH2, and induces differentiation in cells expressing IDH2-R140Q and IDH2-R172K. TQ05310 is utilized in research on acute myeloid leukemia. |
| 靶点活性 | IDH2 R172K:37.9 nM, IDH2 R140Q:136.9 nM |
| 别名 | TQ-05310 |
| 分子量 | 473.38 |
| 分子式 | C19H17F6N7O |
| CAS No. | 2071196-10-4 |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
评论内容